BCL2 and colorectal carcinoma: We recently showed that the therapeutic activity of regorafenib in CRC cells is associated with apoptosis induction and proteasomal degradation of myeloid cell leukemia 1 (Mcl-1), a pro-survival Bcl-2 family protein 6.